Comparative Pharmacology
Head-to-head clinical analysis: IMPEKLO versus SELSUN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPEKLO versus SELSUN.
IMPEKLO vs SELSUN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPEKLO (omalizumab) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits binding of IgE to the high-affinity FcεRI receptor on mast cells and basophils, reducing activation and release of mediators in allergic responses.
Selenium sulfide is an antifungal agent that inhibits the growth of Malassezia species by reducing selenium to elemental selenium, which is toxic to the fungus. It also reduces sebum production via unknown mechanisms.
IMPEKLO is not a recognized pharmaceutical agent. No dosing information available.
Apply 5-10 mL of 2.5% selenium sulfide lotion to affected areas of scalp, lather with water, leave on for 2-3 minutes, then rinse thoroughly. Use twice weekly for 2 weeks, then once weekly for maintenance.
None Documented
None Documented
The terminal elimination half-life of IMPEKLO is 8-12 hours in healthy adults, prolonged in renal impairment (up to 24-36 hours).
Not well defined due to minimal systemic absorption; topical application yields negligible plasma levels.
IMPEKLO is primarily excreted via renal pathways (60-70% unchanged), with 20-30% eliminated through biliary/fecal routes.
Selenium sulfide is minimally absorbed; absorbed portions are excreted renally (approx. 80-90%) and fecally (10-20%).
Category C
Category C
Antifungal
Antifungal/Antiseborrheic